Core Viewpoint - The company is undergoing a leadership change with the resignation of the former general manager and the appointment of a new non-independent director and general manager, Li Jinqiu, to ensure stable operations and governance [1][2][3]. Group 1: Board Restructuring - The former general manager, Lu Junqiang, resigned due to work adjustments, prompting the need for a new non-independent director and general manager [1]. - The board of directors approved the nomination of Li Jinqiu as a non-independent director candidate and his appointment as the general manager, pending shareholder approval [2][10]. Group 2: Upcoming Shareholder Meeting - The company plans to hold its third extraordinary general meeting on December 29, 2025, to discuss the board restructuring and other matters [12][15]. - The meeting will utilize both on-site and online voting methods, with specific timeframes for participation [16][19]. Group 3: Investment and Acquisition Strategy - The company intends to change part of its fundraising project to acquire a 55% stake in Suzhou Jiesibai Medical Technology Co., Ltd. for 86.46 million yuan, enhancing its competitive position in the orthopedic minimally invasive segment [40][46]. - This acquisition aligns with the company's strategic focus on expanding its product offerings in the orthopedic field, particularly in minimally invasive and energy-based devices [47][49].

Core Viewpoint - Weigao Orthopedics (688161) plans to utilize 86.46 million yuan of unallocated fundraising from the "R&D Center Construction Project" to acquire a stake in Suzhou Jiesibai Medical Technology Co., Ltd. (referred to as "Jiesibai") and increase its capital, resulting in the company holding 55% of Jiesibai's shares and consolidating it into its financial statements [1] Group 1 - The acquisition will enhance Weigao's capabilities in minimally invasive orthopedic products and energy-based devices, aligning with the focus of its R&D Center [1] - Jiesibai specializes in spinal minimally invasive and sports medicine, possessing two major technology platforms in minimally invasive orthopedic and energy-based devices [1] - The collaboration is expected to strengthen Weigao's technological accumulation in high-frequency electric knives, surgical power systems, and ultrasonic bone knives, further enhancing its advantages in minimally invasive products such as spinal and arthroscopic surgical products [1]

Core Viewpoint - Weigao Orthopedics (688161.SH) plans to change the use of 86.46 million yuan of unutilized funds from its "R&D Center Construction Project" to acquire a stake in Suzhou Jiesibai Medical Technology Co., Ltd. and increase its capital, resulting in a 55% ownership stake in Jiesibai [1] Group 1: Company Acquisition - The company will invest 86.46 million yuan to acquire part of the equity of Jiesibai and increase its capital [1] - After the transaction, the company will hold a 55% stake in Jiesibai, which will be included in the consolidated financial statements [1] Group 2: Jiesibai Overview - Jiesibai focuses on minimally invasive spine and sports medicine, possessing two major technology platforms: orthopedic minimally invasive and active energy devices [1] - Key products include percutaneous spinal endoscopes, orthopedic joint endoscopes, ultrasonic bone knives, medical endoscope imaging systems, high-frequency electric knives, and various supporting instruments and consumables [1] - The company has strong R&D capabilities in the fields of minimally invasive orthopedic products and active energy products [1]